Meeting
2023 ASCO Annual Meeting
The clinical feasibility of circulating tumor DNA alterations in patients with advanced hepatocellular carcinoma.
Authors
Gwangil Kim
Department of Pathology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea
Gwangil Kim , Sohyun Hwang , Haeyoun Kang , Jaekyung Cheon , Beodeul Kang , Chan Kim , Hong Jae Chon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4110)
DOI
10.1200/JCO.2023.41.16_suppl.4110
Abstract #
4110
Poster Bd #
431
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: Darren Cowzer
Poster
2023 ASCO Annual Meeting
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.
First Author: Natalie Danziger
Poster
2021 ASCO Annual Meeting
Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.
First Author: Jonathan Poh
Poster
2021 Genitourinary Cancers Symposium
Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.
First Author: Pedro C. Barata